NCT07142837View on ClinicalTrials.gov

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

153

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

ZG005

ZG005 20mg/kg; once every 3 weeks；IV infusion

DRUG

Gecacitinib

Gecacitinib for dose escalations are set as 100mg Bid po. Gecacitinib for dose expansion will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.

Trial Locations (1)

Unknown

Chinese PLA General Hosptial, Beijing

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY